SIAMAB THERAPEUTICS
Siamab Therapeutics is a biopharmaceutical company that develops therapies targeting abnormal carbohydrates found only on cancer cells. It has developed a platform of technologies that enables the discovery and development of anti-TACA therapeutic antibodies. The companyโs core technologies were licensed from the laboratory of Ajit Varki, a professional in glycobiology and sialic-acid biochemistry. It has brought together a team of scientists and advisors in oncology, glycoimmunology, and antibody engineering to support its anti-TACA antibody discovery and development programs. Siamab Therapeutics was founded in 2006 and is headquartered in Newton, M.A.
SIAMAB THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2006-01-01
Address:
Newton, Massachusetts, United States
Country:
United States
Website Url:
http://www.siamab.com
Total Employee:
1+
Status:
Closed
Contact:
(800) 513-1569
Email Addresses:
[email protected]
Total Funding:
6.63 M USD
Technology used in webpage:
Google Apps For Business Wix DNS
Current Advisors List
Current Employees Featured
Founder
Investors List
Maine Angels
Maine Angels investment in Venture Round - Siamab Therapeutics
Maine Angels
Maine Angels investment in Venture Round - Siamab Therapeutics
LaunchPad Venture
LaunchPad Venture investment in Series B - Siamab Therapeutics
Desert Angels
Desert Angels investment in Series B - Siamab Therapeutics
Maine Angels
Maine Angels investment in Series B - Siamab Therapeutics
Boston Harbor Angels
Boston Harbor Angels investment in Series B - Siamab Therapeutics
Beacon Angels
Beacon Angels investment in Series B - Siamab Therapeutics
Mass Medical Angels
Mass Medical Angels investment in Series B - Siamab Therapeutics
Boston Harbor Angels
Boston Harbor Angels investment in Series B - Siamab Therapeutics
Mass Medical Angels
Mass Medical Angels investment in Series B - Siamab Therapeutics
Official Site Inspections
http://www.siamab.com
- Host name: 64.190.63.222
- IP address: 64.190.63.222
- Location: Cleveland United States
- Latitude: 41.5043
- Longitude: -81.6786
- Metro Code: 510
- Timezone: America/New_York
- Postal: 44114
More informations about "Siamab Therapeutics"
Siamab Therapeutics - Crunchbase Company Profile
Siamab Therapeutics is a biopharmaceutical company that develops therapies targeting abnormal carbohydrates found only on cancer cells. It has developed โฆSee details»
Siamab Therapeutics, Inc.: Contact Details and Business Profile
Siamab Therapeutics (formerly Sialix, Inc.) is a biopharmaceutical company developing novel cancer immunotherapies. Siamab has developed a platform of technologies that enable the โฆSee details»
Siamab Therapeutics 2025 Company Profile: Valuation, โฆ
Siamab Therapeutics General Information Description. Developer of a technology platform designed to develop therapies targeting cancers. The company's โฆSee details»
Siamab - 2025 Company Profile, Funding & Competitors - Tracxn
Siamab is a deadpooled company based in Newton (United States), founded in 2006 by Ajit Varki. It operates as a Monoclonal antibodies for cancer.Siamab has raised $9.65M in funding from โฆSee details»
SIAMAB THERAPEUTICS, INC. - VentureRadar
Siamab Therapeutics is a biopharmaceutical company developing novel cancer immunotherapies. Siamab has developed a platform of technologies that enable the rapid discovery and โฆSee details»
Siamab Therapeutics, Inc. Overview | SignalHire Company Profile
Siamab Therapeutics, Inc. is a private company that has been in the industry for 17 years. The company currently specializes in the Pharmaceuticals area ... Organization Website: โฆSee details»
Siamab Therapeutics, Inc. | Newton, MA, US Startup - Gust
Siamab's platform enables the rapid creation of multiple antibodies to these challenging targets. Team Jeff Behrens President and CEO. Jeff worked formerly at Edimer (funded by Third โฆSee details»
Siamab Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Last update 23 Jan 2025. Siamab Therapeutics, Inc. Private Company |See details»
Siamab Therapeutics, Inc.:Company Profile & Technical Research ...
Siamab Therapeutics, Inc. is a company that provides Medical equipment, Pharmacy and Therapeutics, Antibody and more. Siamab Therapeutics, Inc. is headquartered in United โฆSee details»
Siamab Therapeutics - Craft
Siamab Therapeutics is a biopharmaceutical company that develops glycan-targeted cancer therapeutics. Its platform technology enables the discovery and development of therapeutic โฆSee details»
Siamab Therapeutics Inc - Company Profile and News
Company profile page for Siamab Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Siamab Therapeutics - Overview, News & Similar companies
Siamab Therapeutics, Inc. is a biopharmaceutical company developing novel cancer therapeutics targeting cancer-specific carbohydrate antigens acros s multiple solid tumors. Siamab's โฆSee details»
Siamab Therapeutics - Funding, Financials, Valuation & Investors
Siamab Therapeutics is funded by 6 investors. Maine Angels and Maine Angels are the most recent investors. Siamab Therapeutics has a post-money valuation in the range of $10M to โฆSee details»
SIAMAB THERAPEUTICS, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for SIAMAB THERAPEUTICS, Inc. of Newton, MA. Get the latest business insights from Dun & Bradstreet.See details»
Siamab Therapeutics - Contacts, Employees, Board Members
Organization. Siamab Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Highlights. Employee Profiles 2. ... Siamab Therapeutics has 14 โฆSee details»
Angel-Funded Siamab Completes $202 Million Exit with Large โฆ
Aug 19, 2019 Corporate Contact: Siamab Therapeutics Jenna Stein, 857-222-5817 [email protected] Media Contact: Rozen Communications Michele Rozen, 617-730-8284 โฆSee details»
Siamab Therapeutics, Inc. (Siamab Therapeutics, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ โฆ
โJohn has successfully guided many biotech companies through key stages in their evolution and he is a tremendous resource for our organization.โ John brings over 35 years of experience in โฆSee details»
Siamab Therapeutics Announces Publication in PLOS ONE of โฆ
Jul 27, 2018 NEWTON, Mass.--(BUSINESS WIRE)-- Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, today โฆSee details»
Antibody-drug Conjugate Information | ADCdb
Organization: Siamab Therapeutics, Inc. Drug Status: Clinical candidate. Indication: In total 1 Indication(s) Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z] Clinical candidate. Structure: 3D โฆSee details»
Siamab Therapeutics and Boehringer Ingelheim Announce โฆ
Oct 4, 2017 Siamab Therapeutics, Inc. is a biopharmaceutical company developing novel cancer immunotherapies targeting tumor-associated carbohydrate antigens (TACAs) seen in multiple โฆSee details»